TNFRSF1A and fibrosarcoma: Blockade of TNFR with TNFRII.Ig, anti-TNF antibodies, or via anti-LTα treatment reduced TU-HEV areas specifically in Treg-depleted fibrosarcomas, while LTbR-Ig had no effect (108).